• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Centene Corporation filed SEC Form 8-K: Regulation FD Disclosure

    9/10/25 9:40:56 PM ET
    $CNC
    Medical Specialities
    Health Care
    Get the next $CNC alert in real time by email
    cnc-20250911
    0001071739false00010717392025-09-112025-09-11



    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    FORM 8-K

    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): September 11, 2025

    CENTENE CORPORATION
    (Exact Name of Registrant as Specified in Charter)

    Delaware001-3182642-1406317
    (State or Other Jurisdiction
    of Incorporation)
    (Commission File Number)
    (IRS Employer
    Identification No.)
    7700 Forsyth Boulevard,
    St. Louis,Missouri63105
    (Address of Principal Executive Offices)(Zip Code)
    Registrant’s telephone number, including area code: (314) 725-4477
    (Former Name or Former Address, if Changed Since Last Report): N/A
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
    ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common stock, $0.001 Par Value
    CNC
    New York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
     
    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




    ITEM 7.01 REGULATION FD DISCLOSURE

    Centene Corporation (the Company) will be participating at the Deutsche Bank 2025 Healthcare Summit on Thursday, September 11, 2025, at 8:00 a.m. EDT. Members of management will discuss the Company’s business and financial results through August, which are consistent with its previously-issued full year 2025 forecast of approximately $1.75 adjusted diluted earnings per share (EPS).

    A simultaneous live audio webcast of Centene's participation in the summit on September 11 will be available at https://event.webcasts.com/starthere.jsp?ei=1734400&tp_key=905baa0793&tp_special=8. A webcast replay will be available following the presentation via the Company's website at www.centene.com, under the Investors section.

    Non-GAAP Financial Presentation

    The Company is providing certain non-GAAP financial measures in this Form 8-K as the Company believes that these figures are helpful in allowing investors to more accurately assess the ongoing nature of the Company's operations and measure the Company's performance more consistently across periods. The Company uses the presented non-GAAP financial measures internally in evaluating the Company's performance and for planning purposes, by allowing management to focus on period-to-period changes in the Company's core business operations, and in determining employee incentive compensation. Therefore, the Company believes that this information is meaningful in addition to the information contained in the GAAP presentation of financial information. The Company strongly encourages investors to review its consolidated financial statements and publicly filed reports in their entirety and cautions investors that the non-GAAP financial measures used by the Company may differ from similar measures used by other companies, even when similar terms are used to identify such measures. The presentation of non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP.

    Specifically, the Company believes the presentation of non-GAAP financial measures that excludes amortization of acquired intangible assets, acquisition and divestiture related expenses, as well as other items, allows investors to develop a more meaningful understanding of the Company's core performance over time. The Company is unable to provide a reconciliation of its 2025 adjusted diluted EPS forecast to the most directly comparable GAAP financial measure without unreasonable effort due to the difficulty of predicting the timing and amounts of various items within a reasonable range.

    Forward-Looking Statements

    All statements, other than statements of current or historical fact, contained in this Form 8-K are forward-looking statements. Without limiting the foregoing, forward-looking statements often use words such as "believe," "anticipate," "plan," "expect," "estimate," "guidance," "intend," "seek," "target," "goal," "may," "will," "would," "could," "should," "can," "continue" and other similar words or expressions (and the negative thereof). Centene Corporation and its subsidiaries (Centene, the Company, our or we) intends such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and we are including this statement for purposes of complying with these safe-harbor provisions. In particular, these statements include, without limitation, statements about our expected future operating or financial performance, changes in laws and regulations, market opportunity, expectations concerning pricing actions, competition, expected contract start dates and terms, expected activities in connection with completed and future acquisitions and dispositions, our investments, and the adequacy of our available cash resources. These forward-looking statements reflect our current views with respect to future events and are based on numerous assumptions and assessments made by us in light of our experience and perception of historical trends, current conditions, business strategies, operating environments, future developments, and other factors we believe appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties and are subject to change because they relate to events and depend on circumstances that will occur in the future, including economic, regulatory, competitive, and other factors that may cause our or our industry's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties, and assumptions. All forward-looking statements included in this Form 8-K are based on information available to us on the date hereof. Except as may be otherwise required by law, we undertake no obligation to update or revise the forward-looking statements included in this Form 8-K, whether as a result of new information, future events, or otherwise, after the date hereof. You should not place undue reliance on any forward-looking statements, as actual results may differ materially from projections, estimates, or other forward-looking statements due to a variety of important factors, variables, and events including, but not limited to: our ability to design and price products that are competitive and/or actuarially sound; our ability to accurately predict and effectively manage health benefits and other operating expenses and reserves, including fluctuations in medical costs; rate cuts, insufficient rate changes or other payment reductions or delays by government payors affecting our government businesses; the effect of social,



    economic, and political conditions, geopolitical events and state and federal policies, including the amount and terms of state and federal funding for government-sponsored healthcare programs, including as a result of changes in U.S. presidential administrations or Congress; changes in federal or state laws or regulations, including changes with respect to income tax reform or government healthcare programs as well as changes with respect to the Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation Act (collectively referred to as the ACA) and any regulations enacted thereunder, including the timing and terms of renewal or modification of the enhanced advance premium tax credits or program integrity initiatives that could have the effect of reducing membership or profitability of our products; unanticipated increased healthcare costs, including due to changes in consumer and provider behaviors, inflation and tariffs; our ability to maintain or achieve improvement in the Centers for Medicare and Medicaid Services (CMS) Star ratings and maintain or achieve improvement in other quality scores in each case that could impact revenue and future growth; competition, including for providers, broker distribution networks, contract reprocurements and organic growth; our ability to adequately anticipate demand and timely provide for operational resources to maintain service level requirements in compliance with the terms of our contracts and state and federal regulations; our ability to comply with the terms of our contracts and state and federal regulations and our ability to effectively oversee our third-party vendors to comply with the terms of their contracts with us and state and federal regulations; our ability to manage our information systems effectively; disruption, unexpected costs, or similar risks from business transactions, including acquisitions, divestitures, and changes in our relationships with third-party vendors; impairments to real estate, investments, goodwill and intangible assets; changes in senior management, loss of one or more key personnel or an inability to attract, hire, integrate and retain skilled personnel; membership and revenue declines or unexpected trends; changes in healthcare practices, new technologies, and advances in medicine; our ability to effectively and ethically use artificial intelligence and machine learning in compliance with applicable laws; changes in macroeconomic conditions, including inflation, interest rates and volatility in the financial markets; negative public perception of the Company and the managed care industry; uncertainty concerning government shutdowns, debt ceilings or funding; tax matters; disasters, climate-related incidents, acts of war or aggression or major epidemics; changes in expected contract start dates and terms; changes in provider, broker, vendor, state, federal and other contracts and delays in the timing of regulatory approval of contracts, including due to protests and our ability to timely comply with any such changes to our contractual requirements or manage any unexpected delays in regulatory approval of contracts; the expiration, suspension, or termination of our contracts with federal or state governments (including, but not limited to, Medicaid, Medicare or other customers); the difficulty of predicting the timing or outcome of legal or regulatory audits, investigations, proceedings or matters including, but not limited to, our ability to resolve claims and/or allegations on acceptable terms, or at all, or whether additional claims, reviews or investigations will be brought; challenges to our contract awards; cyber-attacks or other data security incidents or our failure to comply with applicable privacy, data or security laws and regulations; the exertion of management's time and our resources, and other expenses incurred and business changes required in connection with complying with the terms of our contracts and the undertakings in connection with any regulatory, governmental, or third party consents or approvals for acquisitions or dispositions; any changes in expected closing dates, estimated purchase price, or accretion for acquisitions or dispositions; losses in our investment portfolio; restrictions and limitations in connection with our indebtedness; a downgrade of our corporate family rating, issuer rating or credit rating of our indebtedness; the availability of debt and equity financing on terms that are favorable to us and risks and uncertainties discussed in the reports that Centene has filed with the Securities and Exchange Commission (SEC). This list of important factors is not intended to be exhaustive. We discuss certain of these matters more fully, as well as certain other factors that may affect our business operations, financial condition, and results of operations, in our filings with the SEC, including our annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. Due to these important factors and risks, we cannot give assurances with respect to our future performance, including without limitation our ability to maintain adequate premium levels or our ability to control our future medical and selling, general and administrative costs. The guidance in this Form 8-K is only effective as of the date given and will not be updated or affirmed unless and until we publicly announce updated or affirmed guidance.




    SIGNATURE
    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    CENTENE CORPORATION
    Date:September 11, 2025By:/s/ Christopher A. Koster
    Christopher A. Koster
    Executive Vice President, Secretary and General Counsel



    Get the next $CNC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CNC

    DatePrice TargetRatingAnalyst
    7/28/2025$38.00Overweight → Neutral
    Cantor Fitzgerald
    7/23/2025$30.00Overweight → Equal Weight
    Wells Fargo
    7/21/2025$33.00Buy → Hold
    TD Cowen
    7/16/2025$30.00Neutral → Underperform
    BofA Securities
    7/10/2025$33.00Overweight → Equal-Weight
    Morgan Stanley
    7/2/2025$45.00Buy → Neutral
    UBS
    7/2/2025$48.00Overweight → Neutral
    Analyst
    6/9/2025$70.00Overweight
    Morgan Stanley
    More analyst ratings

    $CNC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: New insider Burdick Kenneth A claimed ownership of 360,802 shares (SEC Form 3)

    3/A - CENTENE CORP (0001071739) (Issuer)

    8/11/25 5:37:15 PM ET
    $CNC
    Medical Specialities
    Health Care

    Chief Executive Officer London Sarah bought $490,365 worth of shares (19,230 units at $25.50), increasing direct ownership by 2% to 845,275 units (SEC Form 4)

    4 - CENTENE CORP (0001071739) (Issuer)

    8/11/25 5:28:22 PM ET
    $CNC
    Medical Specialities
    Health Care

    Director Samuels Theodore R. Ii bought $248,580 worth of shares (9,000 units at $27.62) (SEC Form 4)

    4 - CENTENE CORP (0001071739) (Issuer)

    7/29/25 6:01:58 PM ET
    $CNC
    Medical Specialities
    Health Care

    $CNC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer London Sarah bought $490,365 worth of shares (19,230 units at $25.50), increasing direct ownership by 2% to 845,275 units (SEC Form 4)

    4 - CENTENE CORP (0001071739) (Issuer)

    8/11/25 5:28:22 PM ET
    $CNC
    Medical Specialities
    Health Care

    Director Samuels Theodore R. Ii bought $248,580 worth of shares (9,000 units at $27.62) (SEC Form 4)

    4 - CENTENE CORP (0001071739) (Issuer)

    7/29/25 6:01:58 PM ET
    $CNC
    Medical Specialities
    Health Care

    Director Greco Thomas bought $1,015,750 worth of shares (17,000 units at $59.75), increasing direct ownership by 736% to 19,309 units (SEC Form 4)

    4 - CENTENE CORP (0001071739) (Issuer)

    12/19/24 5:39:30 PM ET
    $CNC
    Medical Specialities
    Health Care

    $CNC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Centene downgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald downgraded Centene from Overweight to Neutral and set a new price target of $38.00

    7/28/25 8:33:52 AM ET
    $CNC
    Medical Specialities
    Health Care

    Centene downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Centene from Overweight to Equal Weight and set a new price target of $30.00

    7/23/25 7:38:36 AM ET
    $CNC
    Medical Specialities
    Health Care

    Centene downgraded by TD Cowen with a new price target

    TD Cowen downgraded Centene from Buy to Hold and set a new price target of $33.00

    7/21/25 8:26:59 AM ET
    $CNC
    Medical Specialities
    Health Care

    $CNC
    SEC Filings

    View All

    Centene Corporation filed SEC Form 8-K: Regulation FD Disclosure

    8-K - CENTENE CORP (0001071739) (Filer)

    9/10/25 9:40:56 PM ET
    $CNC
    Medical Specialities
    Health Care

    Centene Corporation filed SEC Form 8-K: Leadership Update

    8-K - CENTENE CORP (0001071739) (Filer)

    8/15/25 4:29:37 PM ET
    $CNC
    Medical Specialities
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Centene Corporation

    SCHEDULE 13G/A - CENTENE CORP (0001071739) (Subject)

    8/14/25 4:16:51 PM ET
    $CNC
    Medical Specialities
    Health Care

    $CNC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Apply Now: Accessibility Improvement Grant Portal Opens for L.A. Interim Housing Providers

    Powered by L.A. Care and Health Net, funding will support accessibility improvement projects that will enhance safety and access for people with disabilities experiencing homelessness in Los Angeles County SACRAMENTO, Calif., Aug. 27, 2025 /PRNewswire/ -- Brilliant Corners, in collaboration with the Los Angeles County Department of Health Services Housing for Health Division, L.A. Care Health Plan, and Health Net, announced the launch of a new website for interim housing providers in Los Angeles County to apply for accessibility-related construction grants. The official website for the Interim Housing Accessibility Improvement Fund opens on August 27, 2025, at 12:00 p.m. PST, with applicatio

    8/27/25 11:00:00 AM ET
    $CNC
    Medical Specialities
    Health Care

    AcariaHealth Sparks Innovation at 2025 Healthcare Advocate Summit with Hackathon and Expert Panels

    LAS VEGAS, Aug. 26, 2025 /PRNewswire/ -- AcariaHealth, a leader in specialty pharmacy solutions and a Centene Corporation company (NYSE:CNC), is taking center stage at the 2025 Healthcare Advocate Summit (Sept. 2–5) in Las Vegas with a first-of-its-kind "Reimagine Access" Hackathon and two can't-miss expert sessions. Reimagine Access: A Hackathon for Healthcare AdvocatesTuesday, Sept. 2 | 1:00–3:30 PM PT | Florentine 1–11 This dynamic, hands-on session brings together healthcare advocates, providers, and pharmacy professionals for fast-paced, themed breakout discussions focuse

    8/26/25 8:40:00 AM ET
    $CNC
    Medical Specialities
    Health Care

    Superior HealthPlan Helps 45,000 Texans Gear Up for School at 88 Community Events

    The events gave students access to health checkups, school supplies, and other resources ahead of the 2025-26 school year. AUSTIN, Texas, Aug. 26, 2025 /PRNewswire/ -- Superior HealthPlan ("Superior"), a leading managed care organization in Texas and a company of Centene (NYSE:CNC), participated in 88 back-to-school events in July and August, providing more than $32,000 in funding to support students as they prepare for a new school year. In all, 45,000 people attended the events in 46 communities across Texas. "The beginning of a school year should be filled with excitement,

    8/26/25 7:00:00 AM ET
    $CNC
    Medical Specialities
    Health Care

    $CNC
    Financials

    Live finance-specific insights

    View All

    CENTENE CORPORATION REPORTS SECOND QUARTER 2025 RESULTS

    -- Diluted Loss Per Share of $(0.51); Adjusted Diluted Loss Per Share of $(0.16) -- ST. LOUIS, July 25, 2025 /PRNewswire/ -- Centene Corporation (NYSE:CNC) (the Company) announced today its financial results for the second quarter ended June 30, 2025. In summary, the 2025 second quarter results were as follows: Total revenues (in millions) $             48,742 Premium and service revenues (in millions) $             42,467 Health benefits ratio 93.0 % SG&A expense ratio 7.1 % Adjusted SG&A expense ratio (1) 7.1 % GAAP diluted loss per share $                (0.51) Adjusted diluted loss per share (1) $                (0.16) Total cash flow provided by operations (in millions) $              

    7/25/25 6:00:00 AM ET
    $CNC
    Medical Specialities
    Health Care

    CENTENE CORPORATION TO HOST 2025 SECOND QUARTER FINANCIAL RESULTS EARNINGS CALL

    CALL MOVED TO 8AM ET ST. LOUIS, July 22, 2025 /PRNewswire/ -- Centene Corporation (NYSE:CNC), a leading healthcare enterprise committed to helping people live healthier lives, announced today that it will release its 2025 second quarter financial results at approximately 6:00 a.m. ET on Friday, July 25, 2025, and host a conference call at 8:00 a.m. ET to review the results. Investors and other interested parties are invited to listen to the conference call by dialing 1-877-883-0383 in the U.S. and Canada; +1-412-902-6506 from abroad, including the following Elite Entry Number: 7878291 to expedite caller registration; or via a live, audio webcast on the Company's website at www.centene.com, 

    7/22/25 8:00:00 AM ET
    $CNC
    Medical Specialities
    Health Care

    CENTENE CORPORATION REPORTS FIRST QUARTER 2025 RESULTS

    -- Diluted EPS of $2.63; Adjusted Diluted EPS of $2.90 -- First quarter 2025 adjusted diluted EPS of $2.90, up 28% from $2.26 in the first quarter of 2024.17% year-over-year premium and service revenue growth.Membership increases of 29% in Marketplace and 22% in Medicare PDP, compared to the first quarter of 2024.Increased 2025 premium and service revenues guidance by $6.0 billion driven by outperformance in Marketplace enrollment and Medicare member retention.ST. LOUIS, April 25, 2025 /PRNewswire/ -- Centene Corporation (NYSE:CNC) (the Company) announced today its financial results for the first quarter ended March 31, 2025. In summary, the 2025 first quarter results were as follows: Total

    4/25/25 6:00:00 AM ET
    $CNC
    Medical Specialities
    Health Care

    $CNC
    Leadership Updates

    Live Leadership Updates

    View All

    eHealth Announces CEO Succession

    Derrick Duke Appointed Chief Executive Officer After Transition Period Fran Soistman to Retire, Remain on eHealth Board of Directors AUSTIN, Texas, July 29, 2025 /PRNewswire/ -- eHealth, Inc. (NASDAQ:EHTH), a leading private online health insurance marketplace (the "Company"), today announced that the Company's Board of Directors has appointed Derrick Duke as its next Chief Executive Officer. Duke will join eHealth on August 4th 2025, to begin the transition process before officially stepping into the CEO role and joining the Board of Directors on September 18th, 2025. He will succeed Fran Soistman, who, as previously announced, will retire from his role as CEO while continuing to serve on t

    7/29/25 9:00:00 AM ET
    $CNC
    $EHTH
    Medical Specialities
    Health Care
    Specialty Insurers
    Finance

    NVA Appoints Ken Burdick Executive Chairman Ahead of Future IPO

    Board further strengthened with appointment of Mike McFarland as Director National Veterinary Associates Group ("NVA"), a leading veterinary care organization, today announced it has strengthened its Board with the appointments of Ken Burdick as Executive Chairman and Dr. James "Mike" McFarland as Director. These executives bring substantial healthcare and public company experience ahead of the company's future IPO. Burdick is a seasoned public company executive with more than 40 years of healthcare experience. He currently serves as Executive Chairman at LifeStance Health (NASDAQ:LFST), a leading U.S. provider of outpatient mental healthcare. Since joining LifeStance as Chairman and CEO

    5/7/25 2:00:00 PM ET
    $CNC
    $LFST
    Medical Specialities
    Health Care
    Medical/Nursing Services

    CENTENE APPOINTS KENNETH Y. TANJI TO BOARD OF DIRECTORS

    ST. LOUIS, Feb. 24, 2025 /PRNewswire/ -- Centene Corporation (NYSE:CNC) ("the Company") announced today the appointment of Kenneth Y. Tanji to the Centene Board of Directors, effective February 20, 2025. Mr. Tanji will serve on the Company's Audit and Compliance Committee. The appointment of Mr. Tanji expands Centene's Board of Directors to 12 members. Mr. Tanji's finance acumen spans more than three decades and includes deep knowledge of capital optimization strategies, strategic acquisitions, JV partnership models and the use of advanced analytics and technologies to scale g

    2/24/25 4:15:00 PM ET
    $CNC
    Medical Specialities
    Health Care

    $CNC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Centene Corporation

    SC 13G - CENTENE CORP (0001071739) (Subject)

    11/14/24 4:06:01 PM ET
    $CNC
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Centene Corporation

    SC 13G/A - CENTENE CORP (0001071739) (Subject)

    11/13/24 3:02:23 PM ET
    $CNC
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Centene Corporation

    SC 13G/A - CENTENE CORP (0001071739) (Subject)

    11/12/24 9:55:15 AM ET
    $CNC
    Medical Specialities
    Health Care